Literature DB >> 8172230

Pathogenesis and treatment of the anemia of chronic disease.

S B Krantz1.   

Abstract

The anemia of chronic disease may be viewed simply as the anemia that accompanies chronic inflammatory, infectious, or neoplastic disorders. Because these conditions are very common, the anemia of chronic disease is one of the most frequent anemias encountered, and is only second in incidence to iron-deficiency anemia. The anemia of chronic disease is primarily an anemia due to underproduction of red cells, with low reticulocyte production, and is most often a normochromic, normocytic anemia. However, in 30% to 50% of patients, the red cells are hypochromic and microcytic and, most often, the serum iron, total iron-binding capacity, and transferrin saturation are reduced in the presence of adequate iron stores. Although the differential diagnosis includes other underproduction anemias, such as those caused by vitamin and mineral deficiencies, renal failure, endocrinopathies, and myelodysplasia, it generally is easily distinguished from these conditions. Nevertheless, an understanding of the pathogenesis of this condition, as well as a means of alleviating the anemia when the chronic disorder persists, has remained elusive. Recently, major advances have occurred toward understanding the pathogenesis of the anemia of chronic disease and its treatment, and these advances are reviewed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172230     DOI: 10.1097/00000441-199405000-00009

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  11 in total

1.  Natural-resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter.

Authors:  T Goswami; A Bhattacharjee; P Babal; S Searle; E Moore; M Li; J M Blackwell
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

Review 2.  The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy.

Authors:  Christian Thomas; Andreas Kirschbaum; Dieter Boehm; Lothar Thomas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Neuroimmune mechanisms in health and disease: 2. Disease.

Authors:  H Anisman; M G Baines; I Berczi; C N Bernstein; M G Blennerhassett; R M Gorczynski; A H Greenberg; F T Kisil; R D Mathison; E Nagy; D M Nance; M H Perdue; D K Pomerantz; E R Sabbadini; A Stanisz; R J Warrington
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

4.  Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset.

Authors:  H R Peeters; M Jongen-Lavrencic; A N Raja; H S Ramdin; G Vreugdenhil; F C Breedveld; A J Swaak
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

5.  Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients.

Authors:  N Charuruks; N Voravud; W Limpanasithikul
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

6.  Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.

Authors:  H R Peeters; M Jongen-Lavrencic; G Vreugdenhil; A J Swaak
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

7.  Solute carrier 11a1 (Slc11a1; formerly Nramp1) regulates metabolism and release of iron acquired by phagocytic, but not transferrin-receptor-mediated, iron uptake.

Authors:  Victoriano Mulero; Susan Searle; Jenefer M Blackwell; Jeremy H Brock
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

8.  Microcytosis and possible early iron deficiency in paediatric inpatients: a retrospective audit.

Authors:  Deepak N Subramanian; Sarah Kitson; Amit Bhaniani
Journal:  BMC Pediatr       Date:  2009-05-29       Impact factor: 2.125

Review 9.  Iron supplementation in the intensive care unit: when, how much, and by what route?

Authors:  Marc Lapointe
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

Review 10.  Anemia and blood transfusion in the critically ill patient: role of erythropoietin.

Authors:  Howard L Corwin
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.